• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed

    2/25/21 3:22:36 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PULM alert in real time by email
    SC 13D 1 sc_13d.htm SCHEDULE 13D Schedule 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    PULMATRIX INC

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    74584P202

    (CUSIP Number)

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108
    +1 345 749 2552

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    February 11, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    1


     

    CUSIP No. 74584P202

     

    13D

     

    Page 2 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Investment Management Ltd

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    928,938

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    928,938

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    928,938

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    1.66%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

    2


     

    CUSIP No. 74584P202

     

    13D

     

    Page 3 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Capital AG

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    928,938

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    928,938

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    928,938

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    1.66%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IA

     

     

     

    3


     

    CUSIP No.74584P202

     

    13D

     

    Page 4 of 6 Pages

     

     

     

     

    Item 1.  Security and Issuer.

    Cusip:

    74584P202

    Issuer:

    Pulmatrix Inc
    99 Hayden Avenue | Suite 390
    Lexington, MA 02421

     

    Item 2.  Identity and Background.

    Name of person filing:

    FiveT Investment Management Ltd
    FiveT Capital AG

    Registered address or principle place of business:

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way,
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108

    FiveT Capital AG
    Allmendstrasse 140, 8041 Zurich, ZH, Switzerland

     

    Item 5.  Interest in Securities of the Issuer.

    As of the date of this Schedule 13D, the Reporting Persons acquired an aggregate of 5,000,000 shares of Common Stock, consisting of 5,000,000 shares held by the FiveT Investment Management Ltd (the “Shares”).  The Shares represent 8.91% of the Common Stock outstanding.  Subsequently, the Reporting Persons sold an aggregate of 4,071,062 Shares.  As of the date of this Schedule 13D, the Reporting Persons beneficially own an aggregate of 928,938 shares of Common Stock. The Shares represent 1.66% of the Common Stock outstanding.

     

    Item 7.  Material to Be Filed as Exhibits.

    Schedule I

     

    4


     

    CUSIP No. 74584P202

     

    13D

     

    Page 5 of 6 Pages

     

     

     

     

     

     

    Schedule I

     

    This Schedule sets forth information with respect to each purchase and sale of Shares which was effectuated by a Reporting Person in the last 60 days since the date of the event which requires filing of this Statement. 

    Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

     

    Trade Date

    Shares Purchased (Sold)

    Price Per Share ($)

    02/11/2021

    5,000,000

    2.00

    02/11/2021

    (2,450,788)

    2.03

    02/11/2021

    (75,300)

    2.22

    02/12/2021

    (674’152)

    1.98

    02/12/2021

    113,945

    1.99

    02/16/2021

    (684,647)

    2.15

    02/17/2021

    (10,560)

    2.17

    02/22/2021

    (289,560)

    2.00

     

     

     

     

     5


     

    CUSIP No. 74584P202

     

    13D

     

    Page 6 of 6 Pages

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    FIVET INVESTMENT MANAGEMENT LTD

    /s/ Wieland Kreuder

    Authorized Person

    February 22, 2021


    6

    Get the next $PULM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PULM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PULM
    Financials

    Live finance-specific insights

    See more
    • Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

      PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass., March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.

      3/30/23 9:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/2/24 9:42:57 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      2/8/23 6:08:04 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/10/23 11:21:19 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

      Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financi

      3/21/25 8:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

      SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the

      1/22/25 8:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pulmatrix and Cullgen Announce Proposed Merger

      Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology Cullgen and Pulmatrix will host an informational webcast about the propose

      11/13/24 9:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $PULM
    SEC Filings

    See more
    • SEC Form 424B3 filed by Pulmatrix Inc.

      424B3 - Pulmatrix, Inc. (0001574235) (Filer)

      5/9/25 4:55:25 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      5/6/25 9:51:14 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      4/17/25 8:39:23 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Batycky Richard P.

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:40 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Varadan Anand

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:42 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cabell Christopher

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:43 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulmatrix with a new price target

      HC Wainwright & Co. reiterated coverage of Pulmatrix with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      4/13/21 6:23:02 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care